Intervacc

Stockholm, November 15, 2023 – On Thursday, November 16, 2023 at 08.30 a.m. (CET) Intervacc AB (publ) will publish the Interim report Q3 (July-September), 2023. Following the report’s publication, Intervacc will arrange a conference call.

CEO Jonas Sohlman and Chief Scientific Officer Andrew Waller will present and comment on the report. A Q&A session will follow after the presentation. The presentation, as well as the Q&A session, will be held in English.

Date and time

Thursday November 16, 2023 at 9.30 a.m. (CET)

Information for participants

If you wish to participate via webcast please use the link below.

Link for participation https://financialhearings.com/event/48875

If you wish to ask questions verbally via the teleconference please register on the link above. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

For more information please contact:  

Jonas Sohlman, CEO
Tel: +46 (0)8 120 10 600
Mob: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.com

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10